Biocon limited Q4 net profit drops 63% to Rs 126 crore

Biocon Limited on Friday reported a 5 per cent rise in consolidated net profit to Rs 126 crore for the fourth quarter ended March 2026, ahead of the 29th edition of the Bengaluru Tech Summit 2026, which will be held from November 17 to 19, 2026 at the Bangalore International Exhibition Centre (BIEC) under the theme ‘AI & Beyond’.
The summit, regarded as one of Asia’s premier technology gatherings, will showcase Karnataka and Bengaluru as global centres of innovation by bringing together industry leaders, researchers, startups, investors and policymakers from across the world. Speaking about the upcoming event, Biocon founder and Executive Chairperson Kiran Mazumdar-Shaw said, “The forthcoming Bangalore Tech Summit between the 17th and 19th of November this year has been christened AI and Beyond. I think innovation is the new mantra for our country's growth towards Viksit Bharat, and AI-led innovation is certainly the new frontier in which India can also participate in a leadership manner.”
She said the summit would focus on all aspects of deep tech, AI-led technology and emerging innovations shaping the future, while reinforcing Karnataka and Bengaluru’s leadership in the technology ecosystem. “I really urge everyone to come to this summit because there's something in it for everyone. Like always, I think Bengaluru and Karnataka are taking the lead,” she added.
Biocon posted total revenue of Rs 4,569 crore during the March quarter, registering a 10 per cent year-on-year growth. The company’s Board of Directors recommended a final dividend of Re 0.50 per share, equivalent to 10 per cent of the face value, for FY26.

Biocon closed #FY26 on a strong note despite a complex geopolitical environment. This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration of our biosimilars and generics business to create one unified biopharma… pic.twitter.com/2pB51fvgOi

— Biocon (@Bioconlimited) May 7, 2026

“Biocon closed FY26 on a strong note, despite a complex geopolitical environment. We delivered margin expansion along with 13 per cent YoY growth in operating revenue, excluding the one-time impact of generic lenalidomide sales last year. This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration,” Mazumdar-Shaw said.The company said FY26 marked a pivotal phase following the integration of its biosimilars and generics businesses into a unified biopharmaceutical enterprise aimed at enhancing global scale, capability and reach.
CEO and Managing Director Shreehas Tambe said the integration has positioned the company for stronger operational efficiencies and long-term growth opportunities.
Biocon incurred an exceptional charge of Rs 80 crore during the quarter, primarily linked to restructuring adjustments and integration-related costs, which weighed on reported earnings. Excluding exceptional items, net profit rose 64 per cent year-on-year to Rs 179 crore, reflecting improved underlying profitability.
Operating revenue for Q4FY26 stood at Rs 4,517 crore on an adjusted basis, while EBITDA rose 29 per cent year-on-year to Rs 1,073 crore. EBITDA margin stood at 23 per cent, supported by operating leverage and improved product mix.
Higher depreciation, finance costs and research spending continued to pressure profitability during the quarter. Depreciation and amortisation expenses increased 18 per cent year-on-year to Rs 513 crore, while finance costs rose 9 per cent to Rs 232 crore. Research and development expenditure climbed 20 per cent to Rs 277 crore amid continued investments in innovation and product pipeline expansion.
Among business segments, biosimilars remained the key growth driver with revenue rising 12 per cent to Rs 2,756 crore, aided by traction in advanced markets and new product launches. The generics business posted revenue of Rs 847 crore, supported by products including liraglutide, while research services arm Syngene International reported a 2 per cent increase in revenue to Rs 1,037 crore.For the full financial year FY26, Biocon reported a 323 per cent rise in net profit to Rs 436 crore, while total income increased 14 per cent to Rs 17,270 crore.
About Biocon Limited
Biocon Limited is an innovation-led global biopharmaceutical company headquartered in Bengaluru, focused on biosimilars, generics and research services. Founded by Kiran Mazumdar-Shaw in 1978, the company operates across more than 120 countries and works on affordable therapies for diabetes, cancer and autoimmune diseases.

(Business Correspondent)